SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Wells Fargo Keeps NovoCure at Equal-Weight, Cuts Target to $15

Wells Fargo maintained its Equal-Weight rating on NovoCure and lowered its price target to $15 from $20.

NVCR

Related stories